Filing Flows › Pharma-Bio Serv (PBSV) › Q1 FY26
Pharma-Bio Serv (PBSV) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Mar 17, 2026
Pharma-Bio Serv (PBSV) reported revenue of $2.3M for the first quarter fiscal 2026 (Q1 FY26), -7% from a year earlier and +7% from the quarter before. Operating margin was -4.1%, net earnings $33K (1.4% of revenue).
Pharma-Bio Serv, Q1 FY26: revenue $2.3M (-7% year over year), operating margin -4.1%, net earnings $33K, operating cash flow −$390K. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.3M | +7% | -7% |
| Operating profit | −$95K | — | — |
| Net earnings | $33K | — | — |
| Operating cash flow | −$390K | -240% | — |
What changed
Revenue was $2.3M in Q1 FY26, down 7% year over year and up 7% from the previous quarter.
Gross margin was 31.5%, up 0.4 points from a year earlier. Operating costs exceeded revenue by $95K, an operating margin of -4.1%. Operating expenses fell 5% while revenue fell 7%. Net earnings were $33K, up 285% year over year. The effective tax rate was 9.9%. Non-operating items added $131K, 359% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$390K. Non-cash charges added back $15K of depreciation and amortization and $9K of share-based compensation. Working capital and other items used $446K. Capital expenditures of $2K exceeded it, leaving free cash flow of −$393K.
Questions
What was Pharma-Bio Serv's revenue in the first quarter fiscal 2026?
Pharma-Bio Serv (PBSV) reported revenue of $2.3M for the first quarter fiscal 2026 (Q1 FY26), -7% from a year earlier and +7% from the quarter before.
Was Pharma-Bio Serv profitable in the first quarter fiscal 2026?
Operating loss was $95K (-4.1% of revenue) and net earnings $33K.
Source: Pharma-Bio Serv 10-Q on SEC EDGAR.